查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1842347

登革熱疫苗市場規模、佔有率和趨勢分析報告：按產品、最終用途、地區和細分市場預測，2025-2033 年

Dengue Vaccine Market Size, Share & Trends Analysis Report By Product (Dengvaxia, Qdenga), By End-user (Government & Public Health Agencies, Hospitals & Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

登革熱疫苗市場摘要

預計 2024 年全球登革熱疫苗市值為 4.2318 億美元，到 2033 年將達到 16.1861 億美元，2025 年至 2033 年的複合年成長率為 13.73%。

登革熱在熱帶和亞熱帶地區的流行日益加劇，對有效疫苗的需求也日益成長。

都市化和人口密度的增加為家貓（病毒的主要蚊媒）創造了有利條件。根據全球證券交易所的數據，2025年4月，巴西共有1,010,833例病例，668例死亡，724例正在調查中，其中聖保羅病例最多，達585,902例。發生率為每10萬人475.5例，低於2024年的每10萬人1,881例。醫護人員和病患意識的提高，加上研究的進展、診所可及性的改善以及與製藥公司的合作的加強，正在加速疫苗的推廣，並支持全球登革熱消除工作。

2025 年 7 月，KFF 健康新聞通報美國各地登革熱病例激增。新增病例數達到約 3,700 例，幾乎是 2023 年約 2,050 例的兩倍。其中，加州、佛羅裡達州和德克薩斯州局部了 105 例，引發了人們對國內傳播的擔憂。從歷史上看，美國大多數登革熱病例與旅行有關，但國內病例的增加表明家貓正在擴大其存在範圍。這種激增反映了環境條件的變化，並強調了以前較少接觸登革熱的社區的風險增加。病例的突然增加凸顯了預防策略的迫切需要，包括接種疫苗、控制蚊蟲和加強監測。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 登革熱疫苗市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

4. 登革熱疫苗市場：產品業務分析

  • 2024年及2033年產品市場佔有率
  • 產品細分儀表板
  • 市場規模、預測與趨勢分析（按產品，2021-2033 年）
  • 登革熱疫苗
  • 庫登加
  • 其他

5. 登革熱疫苗市場：最終用途業務分析

  • 2024年和2033年的最終用途市場佔有率
  • 最終用途細分儀表板
  • 市場規模、預測與趨勢分析（依最終用途，2021-2033 年）
  • 政府和公共衛生機構
  • 醫院和專科診所
  • 其他

6. 登革熱疫苗市場：區域估計與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場儀表板
  • 2021-2033年市場規模與預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Sanofi
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68040-745-6

Dengue Vaccine Market Summary

The global dengue vaccine market size was estimated at USD 423.18 million in 2024 and is projected to reach USD 1,618.61 million by 2033, growing at a CAGR of 13.73% from 2025 to 2033. The increasing prevalence of dengue fever across tropical and subtropical regions drives strong demand for effective vaccines.

The increasing urbanization and population density create favorable conditions for Aedes mosquitoes, the primary carriers of the virus. The increasing frequency of outbreaks highlights urgent preventive needs, as seen in April 2025, when the World Stock Market reported Brazil had registered 1,010,833 probable cases, 668 confirmed deaths, and 724 under investigation, with Sao Paulo leading at 585,902 cases. The incidence rate was 475.5 per 100,000, lower than 1,881 per 100,000 in 2024. The increasing awareness among healthcare providers and patients, combined with advances in research, greater accessibility in clinics, and stronger pharmaceutical collaborations, accelerates vaccine adoption and supports global dengue control efforts.

In July 2025, KFF Health News reported a sharp rise in dengue cases across the contiguous United States. The number of new infections reached approximately 3,700, nearly doubling from about 2,050 cases in 2023. Of these, 105 cases were confirmed to be locally transmitted in California, Florida, and Texas, signaling a concerning trend in domestic spread. Historically, dengue infections in the U.S. were mostly travel-related, but the rising local transmission indicates that the Aedes aegypti mosquito has expanded its presence. This surge reflects changing environmental conditions and highlights growing risks for communities that previously faced minimal exposure to dengue. The sudden escalation of cases underscores an urgent need for preventive strategies, including vaccination, mosquito control, and improved monitoring.

Global Dengue Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dengue vaccine market report based on product, end-user, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Dengvaxia
  • Qdenga
  • Others
  • End-user Outlook (Revenue, USD Million, 2021 - 2033)
  • Government & Public Health Agencies
  • Hospitals & Specialty Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End User
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dengue Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Dengue Vaccine Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Dengvaxia
    • 4.4.1. Dengvaxia Market, 2021 - 2033 (USD Million)
  • 4.5. Qdenga
    • 4.5.1. Qdenga Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Dengue Vaccine Market: End User Business Analysis

  • 5.1. End User Market Share, 2024 & 2033
  • 5.2. End User Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
  • 5.4. Government & Public Health Agencies
    • 5.4.1. Government & Public Health Agencies Market, 2021 - 2033 (USD Million)
  • 5.5. Hospitals & Specialty Clinics
    • 5.5.1. Hospitals & Specialty Clinics Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Dengue Vaccine Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Dengue Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Dengue Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Sanofi
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Takeda Pharmaceutical Company Limited
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global dengue vaccine market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 5 Global dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 6 North America dengue vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 8 North America dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 9 U.S. dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 10 U.S. dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 11 Canada dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 12 Canada dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 13 Mexico dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 14 Mexico dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 15 Europe dengue vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 17 Europe dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 18 UK dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 19 UK dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 20 Germany dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 21 Germany dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 22 France dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 23 France dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 24 Italy dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 25 Italy dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 26 Spain dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 27 Spain dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 28 Norway dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 29 Norway dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 30 Denmark dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 31 Denmark dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 32 Sweden dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 33 Sweden dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific dengue vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific dengue vaccine market, by end user, 2021 - 2033 (USD
  • Table 37 Million)
  • Table 38 Japan dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 39 Japan dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 40 China dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 41 China dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 42 India dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 43 India dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 44 Australia dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 45 Australia dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 46 South Korea dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 47 South Korea dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 48 Thailand dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 49 Thailand dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 50 Latin America dengue vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 51 Latin America dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 52 Latin America dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 53 Brazil dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 54 Brazil dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 55 Argentina dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 56 Argentina dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Dengue vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 59 Middle East & Africa dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 60 South Africa dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 61 South Africa dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 63 Saudi Arabia dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 64 UAE dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 65 UAE dengue vaccine market, by end user, 2021 - 2033 (USD Million)
  • Table 66 Kuwait dengue vaccine market, by product, 2021 - 2033 (USD Million)
  • Table 67 Kuwait dengue vaccine market, by end user, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dengue vaccine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and product outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Dengue vaccine market dynamics
  • Fig. 12 Dengue vaccine market: Porter's five forces analysis
  • Fig. 13 Dengue vaccine market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Dengvaxia market, 2021 - 2033 (USD Million)
  • Fig. 16 Qdenga market, 2021 - 2033 (USD Million)
  • Fig. 17 Others market, 2021 - 2033 (USD Million)
  • Fig. 18 End User market, 2021 - 2033 (USD Million)
  • Fig. 19 Government & Public Health Agencies market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospitals & Specialty Clinics market, 2021 - 2033 (USD Million)
  • Fig. 21 Others market, 2021 - 2033 (USD Million)
  • Fig. 22 Dengue vaccine market revenue, by region
  • Fig. 23 Regional marketplace: Key takeaways
  • Fig. 24 North America dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. country dynamics
  • Fig. 26 U.S. dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 27 Canada country dynamics
  • Fig. 28 Canada dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 29 Mexico country dynamics
  • Fig. 30 Mexico dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 31 Europe dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 32 UK country dynamics
  • Fig. 33 UK dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany country dynamics
  • Fig. 35 Germany dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 36 France country dynamics
  • Fig. 37 France dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 38 Italy country dynamics
  • Fig. 39 Italy dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 40 Spain country dynamics
  • Fig. 41 Spain dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 42 Norway country dynamics
  • Fig. 43 Norway dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 44 Sweden country dynamics
  • Fig. 45 Sweden dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark country dynamics
  • Fig. 47 Denmark dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 48 Asia Pacific dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 49 Japan country dynamics
  • Fig. 50 Japan dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 51 China country dynamics
  • Fig. 52 China dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 53 India country dynamics
  • Fig. 54 India dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 55 Australia country dynamics
  • Fig. 56 Australia dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 57 South Korea country dynamics
  • Fig. 58 South Korea dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 59 Thailand country dynamics
  • Fig. 60 Thailand dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 61 Latin America dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 62 Brazil country dynamics
  • Fig. 63 Brazil dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 64 Argentina country dynamics
  • Fig. 65 Argentina dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 66 MEA dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 67 South Africa country dynamics
  • Fig. 68 South Africa dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 69 Saudi Arabia country dynamics
  • Fig. 70 Saudi Arabia dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 71 UAE country dynamics
  • Fig. 72 UAE dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 73 Kuwait country dynamics
  • Fig. 74 Kuwait dengue vaccine market, 2021 - 2033 (USD Million)
  • Fig. 75 Company categorization
  • Fig. 76 Company market position analysis
  • Fig. 77 Strategic framework